Selected research
Industry Growth & Trends
Global Hepatitis B Therapeutic Drug Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Hepatitis B Therapeutic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Hepatitis B Therapeutic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Hepatitis B Therapeutic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hepatitis B Therapeutic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Hepatitis B Therapeutic Drug market include Bristol-Myers Squibb, Gilead Sciences, Merck & Co. Inc., Mitsubishi Tanabe Pharma, AbbVie, GlaxoSmithKline, Roche, Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Hepatitis B Therapeutic Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Hepatitis B Therapeutic Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatitis B Therapeutic Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatitis B Therapeutic Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Hepatitis B Therapeutic Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Hepatitis B Therapeutic Drug Market by Company
Bristol-Myers Squibb
Gilead Sciences
Merck & Co. Inc.
Mitsubishi Tanabe Pharma
AbbVie
GlaxoSmithKline
Roche
Novartis
Johnson & Johnson
Hepatitis B Therapeutic Drug Segment by Type
Tenofovir
Telbivudine
Lamivudine
Entecavir
Adefovir
Others
Hepatitis B Therapeutic Drug Segment by Application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
Hepatitis B Therapeutic Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Therapeutic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Therapeutic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Therapeutic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Hepatitis B Therapeutic Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tenofovir
- Telbivudine
- Lamivudine
- Entecavir
- Adefovir
- Others
Applications
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Others
Companies covered
- Bristol-Myers Squibb
- Gilead Sciences
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma
- AbbVie
- GlaxoSmithKline
- Roche
- Novartis
- Johnson & Johnson
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Hepatitis B Therapeutic Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Hepatitis B Therapeutic Drug Market Size by Region (2021-2032)
- 1.4.1 Global Hepatitis B Therapeutic Drug Market Size by Region (2021-2026)
- 1.4.2 Global Hepatitis B Therapeutic Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Hepatitis B Therapeutic Drug Market Size (2021-2032)
- 1.5.1 North America Hepatitis B Therapeutic Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Hepatitis B Therapeutic Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Hepatitis B Therapeutic Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Hepatitis B Therapeutic Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Hepatitis B Therapeutic Drug Market Size Growth Rate (2021-2032)
2 Hepatitis B Therapeutic Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Tenofovir
- 2.1.2 Telbivudine
- 2.1.3 Lamivudine
- 2.1.4 Entecavir
- 2.1.5 Adefovir
- 2.1.6 Others
- 2.2 Global Hepatitis B Therapeutic Drug Market Size by Type
- 2.2.1 Global Hepatitis B Therapeutic Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Hepatitis B Therapeutic Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Hepatitis B Therapeutic Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Hepatitis B Therapeutic Drug Market Size by Regions
- 2.3.1 North America Hepatitis B Therapeutic Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Hepatitis B Therapeutic Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Hepatitis B Therapeutic Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Hepatitis B Therapeutic Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Hepatitis B Therapeutic Drug Market Size Breakdown by Type (2021-2026)
3 Hepatitis B Therapeutic Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital Pharmacies
- 3.1.2 Retail Pharmacies & Drug Stores
- 3.1.3 Others
- 3.2 Global Hepatitis B Therapeutic Drug Market Size by Application
- 3.2.1 Global Hepatitis B Therapeutic Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Hepatitis B Therapeutic Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Hepatitis B Therapeutic Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Hepatitis B Therapeutic Drug Market Size by Regions
- 3.3.1 North America Hepatitis B Therapeutic Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Hepatitis B Therapeutic Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Hepatitis B Therapeutic Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Hepatitis B Therapeutic Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Hepatitis B Therapeutic Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Hepatitis B Therapeutic Drug Industry Trends
- 4.2 Hepatitis B Therapeutic Drug Industry Drivers
- 4.3 Hepatitis B Therapeutic Drug Industry Opportunities and Challenges
- 4.4 Hepatitis B Therapeutic Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Hepatitis B Therapeutic Drug Revenue (2021-2026)
- 5.2 Global Hepatitis B Therapeutic Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Hepatitis B Therapeutic Drug Key Company Headquarters & Area Served
- 5.4 Global Hepatitis B Therapeutic Drug Company, Product Type & Application
- 5.5 Global Hepatitis B Therapeutic Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Hepatitis B Therapeutic Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Hepatitis B Therapeutic Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Hepatitis B Therapeutic Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Bristol-Myers Squibb
- 6.1.1 Bristol-Myers Squibb Company Information
- 6.1.2 Bristol-Myers Squibb Business Overview
- 6.1.3 Bristol-Myers Squibb Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Bristol-Myers Squibb Hepatitis B Therapeutic Drug Product Portfolio
- 6.1.5 Bristol-Myers Squibb Recent Developments
- 6.2 Gilead Sciences
- 6.2.1 Gilead Sciences Company Information
- 6.2.2 Gilead Sciences Business Overview
- 6.2.3 Gilead Sciences Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Gilead Sciences Hepatitis B Therapeutic Drug Product Portfolio
- 6.2.5 Gilead Sciences Recent Developments
- 6.3 Merck & Co. Inc.
- 6.3.1 Merck & Co. Inc. Company Information
- 6.3.2 Merck & Co. Inc. Business Overview
- 6.3.3 Merck & Co. Inc. Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck & Co. Inc. Hepatitis B Therapeutic Drug Product Portfolio
- 6.3.5 Merck & Co. Inc. Recent Developments
- 6.4 Mitsubishi Tanabe Pharma
- 6.4.1 Mitsubishi Tanabe Pharma Company Information
- 6.4.2 Mitsubishi Tanabe Pharma Business Overview
- 6.4.3 Mitsubishi Tanabe Pharma Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Mitsubishi Tanabe Pharma Hepatitis B Therapeutic Drug Product Portfolio
- 6.4.5 Mitsubishi Tanabe Pharma Recent Developments
- 6.5 AbbVie
- 6.5.1 AbbVie Company Information
- 6.5.2 AbbVie Business Overview
- 6.5.3 AbbVie Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AbbVie Hepatitis B Therapeutic Drug Product Portfolio
- 6.5.5 AbbVie Recent Developments
- 6.6 GlaxoSmithKline
- 6.6.1 GlaxoSmithKline Company Information
- 6.6.2 GlaxoSmithKline Business Overview
- 6.6.3 GlaxoSmithKline Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 GlaxoSmithKline Hepatitis B Therapeutic Drug Product Portfolio
- 6.6.5 GlaxoSmithKline Recent Developments
- 6.7 Roche
- 6.7.1 Roche Company Information
- 6.7.2 Roche Business Overview
- 6.7.3 Roche Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Roche Hepatitis B Therapeutic Drug Product Portfolio
- 6.7.5 Roche Recent Developments
- 6.8 Novartis
- 6.8.1 Novartis Company Information
- 6.8.2 Novartis Business Overview
- 6.8.3 Novartis Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Novartis Hepatitis B Therapeutic Drug Product Portfolio
- 6.8.5 Novartis Recent Developments
- 6.9 Johnson & Johnson
- 6.9.1 Johnson & Johnson Company Information
- 6.9.2 Johnson & Johnson Business Overview
- 6.9.3 Johnson & Johnson Hepatitis B Therapeutic Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Johnson & Johnson Hepatitis B Therapeutic Drug Product Portfolio
- 6.9.5 Johnson & Johnson Recent Developments
7 North America
- 7.1 North America Hepatitis B Therapeutic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Hepatitis B Therapeutic Drug Market Size by Country (2021-2026)
- 7.3 North America Hepatitis B Therapeutic Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Hepatitis B Therapeutic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Hepatitis B Therapeutic Drug Market Size by Country (2021-2026)
- 8.3 Europe Hepatitis B Therapeutic Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Hepatitis B Therapeutic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Hepatitis B Therapeutic Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Hepatitis B Therapeutic Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Hepatitis B Therapeutic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Hepatitis B Therapeutic Drug Market Size by Country (2021-2026)
- 10.3 South America Hepatitis B Therapeutic Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Hepatitis B Therapeutic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Hepatitis B Therapeutic Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Hepatitis B Therapeutic Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst